Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.68 |
| ▸ | CTSD | P07339 | 4/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306616 | 0.90 | BACE1 (0.68) | BACE1CTSDCTSB | |
| SCHEMBL13334080 | 0.90 | BACE1 (0.66) | BACE1CTSDBACE2CTSB | |
| SCHEMBL3355052 | 0.90 | BACE1 (0.68) | BACE1CTSDCTSB | |
| SCHEMBL13307641 | 0.90 | BACE1 (0.68) | BACE1CTSDCTSB | |
| SCHEMBL3349885 | 0.89 | BACE1 (0.65) | BACE1CTSDBACE2CTSB | |
| SCHEMBL3177153 | 0.88 | BACE1 (0.76) | BACE1CTSDBACE2CTSB | |
| SCHEMBL3177147 | 0.88 | BACE1 (0.76) | BACE1CTSDBACE2CTSB | |
| SCHEMBL13306181 | 0.88 | BACE1 (0.72) | BACE1CTSDBACE2CTSB | |
| SCHEMBL8075124 | 0.88 | BACE1 (0.72) | BACE1CTSDBACE2CTSB | |
| SCHEMBL13306207 | 0.88 | BACE1 (0.79) | BACE1CTSDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395551-B1 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | ELAN PHARM INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | BACE1 67/4885CTSD 2851/4885BACE2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.